The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation.
about
Ten modifiers of BRCA1 penetrance validated in a Norwegian seriesTumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography.Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality.The BRCA2 variant c.68-7 T>A is associated with breast cancer.Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds.Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families.
P2860
The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The clinical utility of geneti ...... a demonstrable BRCA mutation.
@en
The clinical utility of geneti ...... a demonstrable BRCA mutation.
@nl
type
label
The clinical utility of geneti ...... a demonstrable BRCA mutation.
@en
The clinical utility of geneti ...... a demonstrable BRCA mutation.
@nl
prefLabel
The clinical utility of geneti ...... a demonstrable BRCA mutation.
@en
The clinical utility of geneti ...... a demonstrable BRCA mutation.
@nl
P2093
P2860
P1476
The clinical utility of geneti ...... a demonstrable BRCA mutation.
@en
P2093
Anita Vabø
Anne Irene Hagen
Astrid Stormorken
Lovise Mæhle
Marit Muri Holmen
Pål Møller
P2860
P2888
P304
P356
10.1007/S10549-014-2902-1
P407
P577
2014-03-12T00:00:00Z